Hansoh Pharmaceutical Group company profile
Company profile
Hansoh Pharmaceutical Group has 9,643 employees and is headquartered in Shanghai, China.
Founded in 1995 and headquartered in Shanghai, Hansoh Pharmaceutical Group Company Limited is an investment holding company that develops, manufactures and sells medicines across China. Its products address anti-infection, central nervous system, oncology, metabolic and autoimmune conditions, under brands such as Ameile, Hengmu and XINYUE. Licensing deals with GlaxoSmithKline, Biotheus and Merck Sharp & Dohme cover lung cancer and metabolic candidates, and a separate collaboration with Roche targets antibody-drug conjugate programs.
In the fiscal year ended December 2025, revenue stood at CNY 15.0 billion, up 22.6% on the prior year, while net profit reached CNY 5.6 billion. The company reports 9,643 employees.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Hong Kong SAR China
- Headquarters
- 287 Xiangke Road, 201210, Shanghai
- Employees
- 9,643
- Chief executive
- Huijuan Zhong
- Founded
- 1995
- Fiscal year
- January - December
- Listing
- 3692 · HKEX
- Indices
- Hang Seng
- Currency
- HKD
- ISIN
- KYG549581067
- Website
- hspharm.com
Hansoh Pharmaceutical Group and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Hansoh Pharmaceutical Group3692 | Hong Kong SAR China | $25.82B | 9,643 | 37.3% | 27.6 |
| Divi's LaboratoriesDIVISLAB | India | $31.67B | 11,565 | 34.0% | 88.0 |
| Torrent PharmaceuticalsTORNTPHARM | India | $19B | 18,258 | 22.2% | 78.9 |
| Shionogi4507 | Japan | $17.03B | 6,223 | 31.6% | 11.4 |
| PharmaEssentia6446 | Taiwan | $16.43B | 131 | 40.3% | 59.4 |
| Yunnan Baiyao Group000538 | China | $15.07B | 9,286 | 11.2% | 19.3 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
